Piper Sandler analyst Christopher Raymond maintains $Regeneron Pharmaceuticals (REGN.US)$ with a buy rating, and maintains the target price at $1,195.
According to TipRanks data, the analyst has a success rate of 53.1% and a total average return of 4.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's third-quarter results surpassed expectations marginally in terms of revenue and more significantly regarding earnings per share. However, the performance of the Eylea franchise was a dominant concern. The impending launch of a biosimilar version of Eylea by a competitor has raised questions about the future of the franchise. This includes the pace at which the standard dose market may decline, which may be faster than current market estimates, and the potential negative impact on the high dose variant.
The recent decline in Regeneron's share value is viewed as an overextension. This sentiment is in response to reactions concerning the Pavblu news, the less-than-anticipated Q4 Eylea HD outlook, and the absence of forward-looking growth projections for Eylea.
The stock's decline post-Q3 earnings was somewhat unexpected. This was given the understanding that near- and long-term consensus estimates for the ophthalmology franchise might have been overly optimistic. Nonetheless, it appears that the fundamental fair value of Regeneron is currently well above where the shares are trading.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
派杰投资分析师Christopher Raymond维持$再生元制药公司 (REGN.US)$买入评级，维持目标价1,195美元。
根据TipRanks数据显示，该分析师近一年总胜率为53.1%，总平均回报率为4.4%。
此外，综合报道，$再生元制药公司 (REGN.US)$近期主要分析师观点如下：
Regeneron的第三季度业绩在收入方面略有超出预期，更重要的是每股收益。但是，Eylea系列的表现是一个主要问题。竞争对手即将推出的生物仿制药版本的Eylea引发了人们对该系列未来的质疑。这包括标准剂量市场可能下降的速度（可能比目前的市场估计更快），以及对高剂量变体的潜在负面影响。
Regeneron最近股价的下跌被视为过度扩张。这种情绪是对Pavblu新闻、不如预期的第四季度Eylea HD前景以及Eylea缺乏前瞻性增长预测的反应的回应。
该股在第三季度后收益的下降有些出乎意料。这是因为我们认识到，眼科专营权的短期和长期共识估计可能过于乐观。尽管如此，Regeneron目前的基本公允价值似乎远高于股票的交易价格。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
